Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.
Disruption of latent Epstein-Barr virus (EBV) infection is induced by the key immediate-early protein BZLF1 (or Z, a member of the basic leucine-zipper family), which transactivates the viral early promoters. Viral reactivation is marked by renewed synthesis of early gene products such as EBV early antigen-diffuse (EA-D). Retinoic acid has been previously shown to inhibit reactivation of EBV infection. Retinoic acid responsive receptors are known to act as positively regulating transcription factors but can also negatively regulate AP-1 responsive genes. Here we demonstrate that the retinoic acid receptor alpha (RAR alpha) and retinoid X receptor alpha (RXR alpha) inhibit the ability of the Z protein to transactivate the viral early promoter BMRF1, which directs transcription of EA-D. Z can also reciprocally inhibit RAR alpha- and RXR alpha-induced activation of an autoregulated cellular promoter for the RAR beta gene (BRE) through a non-DNA binding mechanism. RXR alpha inhibits Z from binding to the AP-1 motif in the BMRF1 promoter and, reciprocally, Z inhibits RAR alpha from binding to its retinoic acid response element in the BRE promoter. Furthermore, a glutathione-S-transferase-RXR alpha fusion protein can interact directly with the Z protein. These results suggest that a direct protein-protein interaction between Z (the viral protein) and RAR alpha and RXR alpha (cellular proteins) can modulate the reactivation of latent EBV infection.
University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill.
N D
ND
Sista
J S
JS
Pagano
W
W
Liao
S
S
Kenney
D000818:Animals; D001483:Base Sequence; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D002478:Cells, Cultured; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D004279:DNA, Viral / Q000235:genetics / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D005814:Genes, Viral; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D016350:Leucine Zippers / Q000235:genetics / Q000502:physiology; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009838:Oligodeoxyribonucleotides / Q000138:chemical synthesis / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000378:metabolism; D018168:Receptors, Retinoic Acid; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D047488:Retinoid X Receptors; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology*; D014764:Viral Proteins / Q000235:genetics; D014775:Virus Activation / Q000187:drug effects
C063676:BZLF1 protein, Herpesvirus 4, Human; D002352:Carrier Proteins; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D009838:Oligodeoxyribonucleotides; D011956:Receptors, Cell Surface; D018168:Receptors, Retinoic Acid; D011993:Recombinant Fusion Proteins; D047488:Retinoid X Receptors; D015534:Trans-Activators; D014157:Transcription Factors; D014764:Viral Proteins; D014212:Tretinoin; D015500:Chloramphenicol O-Acetyltransferase